[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020,70:7-30. [2] Nishikawa T, Bellance N, Damm A, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease[J]. J Hepatol, 2014,60:1203-1211. [3] Maximchik P, Abdrakhmanov A, Inozemtseva E, et al. 2-Deoxy-D-glucose has distinct and cell line-specific effects on the survival of different cancer cells upon antitumor drug treatment[J]. FEBS J, 2018,285:4590-4601. [4] Kirschke E, Goswami D, Southworth D, et al. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles [J]. Cell, 2014, 157:1685-1697. [5] Hendrick JP, Hartl FU. Molecular chaperone functions of heat-shock proteins[J]. Annu Rev Biochem, 1993,62:349-384. [6] Huang W, Dong Z, Wang F, et al. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion[J]. ACS Chem Biol, 2014,9:1188-1196. [7] Riebold M, Kozany C, Freiburger L, et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease[J]. Nat Med, 2015,21:276-280. [8] Whitesell L, Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells[J]. Mol Endocrinol, 1996,10:705-712. [9] Jiang T, Zhou ML, Fan J. Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro[J]. Onco Targets Ther, 2018,11:7865-7872. [10] Zhao Y, Yang L, He J, et al. STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma[J]. Tumor Biol, 2017,39:1-8. [11] Giulino-Roth L, van Besien HJ, Dalton T, et al. Inhibit-ion of Hsp90 suppresses PI3K/AKT/mTOR signaling and Has antitumor activity in Burkitt lymphoma[J]. Mol Cancer Ther, 2017,16:1779-1790. |